# Apyx Medical Corp: Form 10-Q for the period ended Sep 30, 2011

- Company: [Apyx Medical Corp](/companies/apyx.md) (CIK 719135)
- Form: 10-Q
- Filed: 2011-11-14
- Accepted by EDGAR: Nov 14, 2011, 07:12 ET
- Period: 2011-09-30
- Accession: 0001140361-11-053005
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/719135/000114036111053005/form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/719135/000114036111053005/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-07-01 to 2011-09-30 | $6.3m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2011-01-01 to 2011-09-30 | $19.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2011-07-01 to 2011-09-30 | $3.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2011-01-01 to 2011-09-30 | $11.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2011-07-01 to 2011-09-30 | $2.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2011-01-01 to 2011-09-30 | $8.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2011-07-01 to 2011-09-30 | $288.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2011-01-01 to 2011-09-30 | $924.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2011-07-01 to 2011-09-30 | $996.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2011-01-01 to 2011-09-30 | $3.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2011-07-01 to 2011-09-30 | $248.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2011-01-01 to 2011-09-30 | $1.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2011-07-01 to 2011-09-30 | −$76.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2011-01-01 to 2011-09-30 | −$439.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-07-01 to 2011-09-30 | $63.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2011-01-01 to 2011-09-30 | $984.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-07-01 to 2011-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2011-01-01 to 2011-09-30 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2011-07-01 to 2011-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2011-01-01 to 2011-09-30 | $0.06 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months, 2011-01-01 to 2011-09-30 | $2.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2011-01-01 to 2011-09-30 | $459.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2011-09-30 | $5.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-09-30 | $16.4m | us-gaap:AssetsCurrent |
| Total assets | at 2011-09-30 | $28.6m | us-gaap:Assets |
| Current liabilities | at 2011-09-30 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-09-30 | $5.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2011-09-30 | $22.7m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2011-10-10 | 17,756,340 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 40,647 characters.

### Cautionary Notes Regarding “Forward-Looking” Statements

This report contains statements that we believe to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended. Forward-looking statements give our current expectations or forecasts of future events. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project,” or “continue,” or similar words or the negative thereof. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Any or all of our forward-looking statements in this report and in any public statements we make could be materially different from actual results. They can be affected by assumptions we might make or by known or unknown risks or uncertainties. Consequently, we cannot guarantee any forward-looking statements. Investors are cautioned not to place undue reliance on any forward-looking statements. Investors should also understand that it is not possible to predict or identify all such factors and should not consider the following list to be a complete statement of all potential risks and uncertainties. The following factors and those discussed in ITEM 1A, Risk Factors, included in our Annual Report on Form 10-K for the year ended December 31, 2010, may affect the achievement of forward-looking statements:

- general economic and political conditions, such as political instability, credit market uncertainty, the rate of economic growth or decline in our principal geographic or product markets or fluctuations in exchange rates; continued deterioration in or stabilization of the global economy;
- changes in general economic and industry conditions in markets in which we participate, such as:
- deterioration in or destabilization of the global economy;
- the strength of product demand and the markets we serve;
- the intensity of competition, including that from foreign competitors;
- pricing pressures;
- the financial condition of our customers;
- market acceptance of new product introductions and enhancements;
- the introduction of new products and enhancements by competitors;
- our ability to maintain and expand relationships with large customers;
- our ability to source raw material commodities from our suppliers without interruption and at reasonable prices; and
- our ability to source components from third parties, in particular from foreign manufacturers, without interruption and at reasonable prices;
- our ability to access capital markets and obtain anticipated financing under favorable terms;
- our ability to identify, complete and integrate acquisitions successfully and to realize expected synergies on our anticipated timetable;
- changes in our business strategies, including acquisition, divestiture and restructuring activities;
- changes in operating factors, such as continued improvement in manufacturing activities, the achievement of related efficiencies and inventory risks due to shifts in market demand;
- our ability to generate savings from our cost reduction actions;
- unanticipated developments that could occur with respect to contingencies such as litigation, intellectual property matters, product liability exposures and environmental matters; and
- our ability to accurately evaluate the effects of contingent liabilities.

The foregoing factors are not exhaustive, and new factors may emerge or changes to the foregoing factors may occur that would impact our business. We assume no obligation, and disclaim any duty, to update the forward-looking statements in this report. Past performance is no guaranty of future results.

### Executive Level Overview

We are a medical device company engaged in manufacturing and marketing of electrosurgical devices. Our medical products include a wide range of devices including electrosurgical generators and accessories, cauteries, medical lighting, nerve locators and other products.

We internally divide our operations into three product lines. Electrosurgical products, battery-operated cauteries and other products. The electrosurgical line sells electrosurgical products which include desiccators, generators, electrodes, electrosurgical pencils and various ancillary disposable products. These products are used in surgery for the cutting and coagulation of tissue. Battery-operated cauteries are used for precise hemostasis (to stop bleeding) in ophthalmology and in other fields. Our other revenues are derived from nerve locators, disposable and reusable penlights, medical lighting, license fees, development fees and other miscellaneous income.

Most of our products currently are marketed through medical distributors, which distribute to more than 6,000 hospitals, and to doctors and other health-care facilities. New distributors are contacted through responses to our advertising in international and domestic medical journals and domestic or international trade shows. International sales represented 22.9% of total revenues for the first nine months of 2011, as compared with 20.9% for the first nine months of 2010. Our products are sold in more than 150 countries mainly through local dealers which are coordinated by sales and marketing personnel at the Clearwater, Florida facility. In addition, for the launch of our new surgical suite product lines, we have established the use of a network of approximately 50 commission-based independent direct sales contractors to market these products. Our business is generally not seasonal in nature.

### Results of Operations –Three and Nine Months Ended September 30, 2011 Compared to Three and Nine Months Ended September 30, 2010

#### Sales

| Sales by Product Line (in thousands) | Three months ended September 30, 2011 | 2010 | Percent change | Nine months ended September 30, 2011 | 2010 | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Electrosurgical | $3,989 | $4,300 | (7.2%) | $12,905 | $11,759 | 9.7% |
| Cauteries | 1,577 | 1,651 | (4.5%) | 4,720 | 4,763 | (0.9%) |
| Other | 690 | 550 | 25.5% | 1,627 | 1,475 | 10.3% |
| Total | $6,256 | $6,501 | (3.8%) | $19,252 | $17,997 | 7.0% |

| Sales by Domestic and International (in thousands) | Three months ended September 30, |  | Percent | Nine months ended September 30, |  | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Domestic | $5,024 | $5,259 | (4.5%) | $14,835 | $14,230 | 4.3% |
| International | 1,232 | 1,242 | (0.8%) | 4,417 | 3,767 | 17.3% |
| Total | $6,256 | $6,501 | (3.8%) | $19,252 | $17,997 | 7.0% |

15

Our sales for the nine months ended September 30, 2011 continue to outpace sales for the same period in 2010 by approximately $1.3 million, even though our third quarter 2011 sales decreased 3.8% or approximately $245,000 from the same period in 2010. The nine month sales increase has been driven mainly by increased demand for our electrosurgical generators both domestically and internationally which amounted to an approximate increase of $1 million or 10.6% or for the nine months ended September 30, 2011 compared to the same period in 2010. Sales of our new distribution products released this year, coated blades which are categorized as electrosurgical and medical lighting systems which are categorized as other products, amounted to increases of approximately $597,000 and $152,000 respectively for the nine months ended compared to the same period in 2010. However, increases in electrosurgical sales were offset by an approximate decrease of $425,000 related to discontinued sales of an OEM disposable electrosurgical device for the nine months ended compared to the same period in 2010. Cautery sales were down fractionally by approximately $40,000 for the nine months ended compared to the same period in 2010.

As mentioned above sales for the third quarter 2011 were lower by approximately $245,000 when compared to the same period 2010 mainly as a result of a decrease in demand for replaceable cauteries in the approximate amount of $74,000 coupled with the effect of us receiving and shipping a larger than usual order from one of our OEM customers in the third quarter 2010 for approximately $311,000. These quarterly decreases were offset by an increase in new distribution medical light products sales of approximately $141,000 in quarter ended September 30, 2011 compared to the same period 2010.

#### Gross Profit

*(in thousands)*

|  | Three months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change | Nine months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of sales | $3,650 | $3,797 | 58.3% | 58.4% | (3.9%) | $11,167 | $10,692 | 58.0% | 59.4% | 4.4% |
| Gross profit | $2,606 | $2,704 | 41.7% | 41.6% | (3.6%) | $8,085 | $7,305 | 42.0% | 40.6% | 10.7% |

We improved our gross profit margin on a dollar basis by 10.7% or approximately $780,000 during the nine months ended September 30, 2011 compared to the same period in 2010 as a result of a combination of increased sales mentioned above and a net reduction in some of our costs attributed to those sales. Our cost of sales as a percentage of sales decreased by 1.4% as a result of reductions approximating $160,000 in direct and indirect labor costs, $142,000 eliminated from our consolidating the Canadian facility, and $37,000 in material and freight cost savings. These reductions were offset by a $61,000 increase in material and subassembly manufacturing consulting costs related to some of our sophisticated components.

Our third quarter 2011 cost of sales as a percentage of sales also improved slightly by a 0.1% decrease compared to the same period in 2010 as we strive to continue the trend of reducing our cost of sales and improving gross margins even though there are many variables that can impact them.

#### Other Gain

On June 10, 2010, we received notice that an action had been commenced against us in the United States Court for the District of Delaware (Civil Action No. 1:10-cv-00494-UNA) by Salient Surgical Technologies, Inc. and Medtronic, Inc. (the “Plaintiffs”). In the complaint, the Plaintiffs alleged that the sale and use of our SEER™ (Saline Enhanced Electrosurgical Resection) fluid-assisted electrosurgical devices infringed on an issued United States patent presently owned by Medtronic and licensed to Salient. The Plaintiffs were demanding a permanent injunction restraining us, and our affiliates, and any person acting in privity or in concert or participation with us from the continued infringement of the patent as well as unspecified monetary damages.

Subsequently, on March 3, 2011 we signed a settlement agreement related to the above-mentioned action with Salient Surgical Technologies, Inc. and Medtronic, Inc. The settlement called for us and related parties to immediately exit and not enter into the monopolar and bipolar saline-enhanced RF device business (including SEER™ and BOSS™) worldwide through February 2015. In exchange, the Plaintiffs made a one-time payment to us of $750,000. We have recognized the full amount as a gain in the first quarter of 2011 as it is economic benefit received for our inventory on hand, some development costs and some reimbursement to offset legal fees incurred in defending this lawsuit. We also reserved for approximately $87,000 of our inventory in the first quarter of 2011. The terms also include a provision outlining a possible OEM contract manufacturing relationship between Salient and our Company. We currently already have a longstanding OEM contract manufacturing agreement with Medtronic for advanced electrosurgical generators. We have given Medtronic notice that the agreement will terminate at December 31, 2011, with final deliveries occurring in 2012. We will continue to service the generators sold during this contract for the next five years. We anticipate sales of accessories and spare parts to continue into the future.

#### Research and Development Expense

*(in thousands)*

|  | Three months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change | Nine months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| R & D expense | $288 | $442 | 4.6% | 6.8% | (34.8%) | $924 | $1,466 | 4.8% | 8.1% | (37.0%) |

We experienced a 34.8% decrease in research and development expense or approximately $154,000 in the third quarter of 2011 compared to the same period in 2010. This decrease was primarily the result of a reduction of $120,000 in R&D engineering costs and $45,000 in R&D labs and materials all related to the sintered steel product line which in March of this year as part of our legal settlement with Salient Surgical Technologies, Inc. we agreed to exit and not enter into the monopolar and bipolar saline-enhanced RF device business (SEER™ and BOSS™) worldwide through February 2015. Our reductions were partially offset by an increase of approximately $11,000 related to additional consulting costs associated with some of our new products under development.

During the nine month period ending September 30, 2011 as compared to the same period in 2010 we had a decrease in research and development expense of 37.0% amounting to approximately $542,000. A large portion of these decreased costs, $320,000 for R&D engineering costs and $112,000 in R&D labs and materials, was attributed to the above mentioned exit out of the monopolar and bipolar saline-enhanced RF device business until February 2015 as part of the Salient Surgical Technologies, Inc. settlement. We also experienced decreased costs related to the vessel sealing product line and the consolidation of that project to our Florida facility from Canada which consisted of approximately $93,000 of reduced R&D consulting costs and $17,000 in other development costs.

#### Professional Fees

*(in thousands)*

|  | Three months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change | Nine months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Professional services | $289 | $556 | 4.6% | 8.6% | (48.0%) | $906 | $1,235 | 4.7% | 6.9% | (26.6%) |

Our professional costs decreased by 48.0% or approximately $267,000 in the third quarter of 2011 compared to the same period in 2010, due mainly to a reduction in legal fees of approximately $163,000 related to settled cases. In addition our tax consulting fees were reduced by approximately $81,000 due to the closing of our IRS audit earlier this year and we had a savings of approximately $23,000 in other consulting costs with our nonrenewal of Growthink which we used in 2010 to support the marketing of new products

For the nine months ended September 30, 2011 as compared to the same period in 2010 we had similar reductions in costs as mentioned above amounting to a 26.6% decrease in professional services expense or approximately $329,000. Theses cost reductions consisted of an approximate $149,000 reduction in legal fees, an approximate $73,000 reduction in tax consulting related to the closed IRS audit, $78,000 reduction in Growthink consulting costs, and a $28,000 reduction in other consulting costs that were incurred in 2010 related to the Canadian facility.

#### Salaries

*(in thousands)*

|  | Three months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change | Nine months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Salaries & related cost | $785 | $782 | 12.5% | 12.0% | 0.4% | $2,391 | $2,386 | 12.4% | 13.3% | 0.2% |

17

Our salaries and related costs remained relatively constant, increasing only 0.4% or approximately $3,000 in the third quarter of 2011 compared to the same period in 2010. Although we experienced an increase in our health insurance premiums of approximately $20,000, this increase was offset by a reduction in salaries related to the elimination of a marketing position for the sintered steel product line that we agreed to exit out of as part of the Salient Surgical Technologies, Inc. settlement.

For the nine month period ending September 30, 2011 as compared to the same period in 2010, we experienced similar offsetting increases and decreases as mentioned above in our salaries and related costs resulting in a slight 0.2% increase, or approximately $5,000. In the past nine months our health insurance costs increased by $39,000 over the first nine months of 2010, and we expect yearly increases for this cost will be the trend in the future. A reduction of an employee position in the marketing department for the sintered steel suspended product line and a decrease associated with consolidating the Canadian operations amounted to offsetting savings of $32,000 and $2,000 respectively.

#### Selling, General & Administrative Expenses

*(in thousands)*

|  | Three months ended September 30 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change | Nine months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| SG & A costs | $996 | $1,039 | 15.9% | 16.0% | (4.1%) | $3,231 | $3,456 | 16.8% | 19.2% | (6.5%) |

Our selling, general and administrative costs decreased by 4.1% overall or approximately $43,000 in the third quarter of 2011 compared to the same period in 2010. We continue to increase sales of our new distribution product lines, coated electrodes and medical lighting systems, and to introduce other new products under development and as a result we had increases in selling costs of $28,000 for advertising, $26,000 for commission expense, and $22,000 for show costs. These selling costs were offset by an approximate $59,000 reduction in travel costs related to the suspension of the sintered steel product line as part of the Salient Surgical Technologies, Inc. settlement. Other components included in the 4.2% overall reduction mentioned above were related to general overhead costs which included approximately $26,000 decrease in amortization expense attributable to the suspension of the sintered steel product line, $23,000 decrease in utilities and facility maintenance costs, $14,000 decrease in regulatory testing costs as a result of our developing products being closer to the end phase than in the prior year, and a $10,000 decrease in loss on disposition of assets which were incurred in the third quarter of 2010. These general overhead decreases were offset by approximate increases when compared to the same period in 2010 of $8,000 in foreign currency loss from the fluctuation in the Euro and a $5,000 increase in costs related to being a public company.

During the nine months ended September 30, 2011 as compared to the same period in 2010 we decreased our selling, general and administrative costs overall by 6.5% or approximately $225,000 which stemmed from several components. One area of cost reductions related to the suspension of the sintered steel product line which resulted in cost savings of approximately $202,000 in marketing, consulting and travel related costs, and the elimination of approximately $76,000 in amortization costs related to the previously impaired patent in 2010, all of which were offset by a reserve for obsolescence cost of $59,000. In addition, we recognized cost savings related to our decision in 2010 to consolidate our Canadian operations to our Florida facility of approximately $267,000, which are offset by our legal settlement cost of approximately $74,000 associated with the Dr. Eisenstein lawsuit. As we experienced in our 2011 third quarter, we similarly had increased selling and marketing expenses for our new distribution and other products of approximately $206,000 for the first nine months of 2011 as compared to the same period in 2010. Other general overhead approximate reductions included $66,000 in utilities and facility costs and $26,000 in foreign currency exchange costs due to the elimination of our exposure to the Canadian dollar fluctuations, while also incurring other general overhead approximate increases of $56,000 in insurance premiums, $9,000 in rents, and $7,000 in public company related costs.

#### Other Income (expense)

*(in thousands)*

|  | Three months ended September 30 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent change | Nine months ended September 30, 2011 | 2010 | Percentage of sales 2011 | 2010 | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest income (expense) | $(42) | $(58) | (0.7%) | (0.9%) | (27.6%) | $(141) | $(169) | (0.7%) | (0.9%) | (16.6%) |
| Change in fair value of liabilities, net | $(67) | $182 | (1.1%) | 2.8% | (136.8%) | $181 | $799 | 0.9% | 4.4% | (77.3%) |

18

Our net interest expense decreased by approximately $16,000 or 27.6% in the three months ended September 30, 2011 and decreased by $28,000 or 16.6% for the nine-month period ended September 30, 2011 as compared to the same respective periods in 2010. Our monthly bond principal payments, which are held in a sinking fund until disbursed and applied against the principal balance one time annually, results in a decrease as the effective fixed interest rate is calculated against significantly different principle balances throughout each of the comparative years.

As a result of the change in fair value of the warrants associated with the equity issuance in April of 2010, we recorded a noncash loss of approximately $51,000 for the 2011 third quarter and noncash income of approximately $162,000 for the nine month period ended September 30, 2011. The derivative warrant liability was valued at approximately $332,000 at December 31, 2010 and was valued at approximately $169,000 at September 30, 2011.

Additional changes in fair value were recognized related to the Lican liability, for which we recorded a noncash loss of approximately $16,000 for the 2011 third quarter and noncash income of approximately $19,000 for the nine months ended September 30, 2011. The fair value of the Lican liability as of December 31, 2010 was $172,200 and the fair value as of September 30, 2011 is $153,300.

#### Income Taxes

*(in thousands)*

|  | Three months ended September 30, 2011 | 2010 | Percent of sales 2011 | 2010 | Percent change | Nine months ended September 30, 2011 | 2010 | Percent of sales 2011 | 2010 | Percent hange |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Income before inc. taxes | $139 | $9 | 2.2% | 0.1% | 1,444% | $1,423 | $(608) | 7.4% | (3.4%) | 334% |
| Benefit (Provision) taxes | $(76) | $(5) | (1.2%) | (0.1%) | 1,420% | $(439) | $442 | (2.3%) | 2.5% | (199%) |
| Effective tax rate | 54.0% | 55.5% |  |  |  | 30.9% | -- |  |  |  |

While we are subject to U.S. federal income tax as well as income tax of certain state jurisdictions, during the three and nine months ended September 30, 2011, our current provisions were zero because the net effect of our permanent and temporary differences resulted in us recognizing losses for tax purposes. At September 30, 2011, we have remaining net operating loss carryforward of approximately $3.3 million to reduce any future taxable income earned in various years through the tax year 2030. Our effective tax rate of 30.9% for the nine months ended September 30, 2011 was less than the statutory tax rates primarily because we recognized certain gains from fair value adjustments for financial statement purposes that are not expected to reverse (i.e. they are considered permanent differences).

#### Net Income (loss)

*(in thousands)*

|  | Three months ended September 30, 2011 | 2010 | Percent of sales 2011 | 2010 | Percent change | Nine months ended September 30, 2011 | 2010 | Percent of sales 2011 | 2010 | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) | $63 | $4 | 1.0% | 0.1% | 1,475% | $984 | $(166) | 5.1% | (0.9)% | 693% |

### Product Development

We have developed most of our products and product improvements internally. Funds for this development have come primarily from our internal cash flow, equity issuance and from the proceeds of the exercise of stock options. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and development. New and improved products play a critical role in our sales growth. We continue to emphasize the development of proprietary products and product improvements to complement and expand our existing product lines. We have a centralized research and development focus in Florida for new product development and product improvements. Our research, development and engineering units at the manufacturing locations maintain relationships with distribution locations and customers to provide an understanding of changes in the market and product needs. During 2011, we continued to invest in the ICON GS™ (J-Plasma™ technology), ICON VS™, vessel sealing technology, and Aaron™ 1450. We intend to pay the ongoing costs for this development from operating cash flows.

At this time, we do not contemplate any material purchase or acquisition of assets during the next twelve months that our ordinary cash flow and/or credit line would be unable to sustain.

### Reliance on Collaborative, Manufacturing and Selling Arrangements

We depend on certain contractual OEM customers for product development. In these situations, we plan to manufacture the products developed. The customer has no legal obligation, however, to purchase the developed products. If the collaborative customer fails to give us purchase orders for the product after development, our future business and value of related assets could be negatively affected. Furthermore, we can give no assurance that a collaborative customer may give sufficient high priority to our products. In addition, disagreements or disputes may arise between us and our contractual customers, which could adversely affect production of our products. We also have informal collaborative arrangements with two foreign suppliers in which we request the development of certain items and components, and we purchase them pursuant to purchase orders. Our purchase orders are never longer than one year and are supported by orders from our customers.

### Liquidity and Capital Resources

Our working capital at September 30, 2011 increased by approximately $1.3 million to $14.4 million compared to approximately $13.1 million at December 31, 2010. This increase was mainly the result of an increase in cash due to the $750,000 received from the Salient and Medtronic settlement (See below Part II, Item 1. Legal Proceedings) and increased sales, as well as an improvement in our average accounts receivable turnover. Accounts receivable days sales outstanding were 34.8 days and 46.3 days at September 30, 2011 and 2010, respectively. The number of days worth of sales in inventory, which is the total inventory available for production divided by the 12 month average cost of materials, decreased 17 days to 239 days equating to an inventory turn ratio of 1.3 at September 30, 2011 from 256 days and an inventory turn ratio of 1.3 at December 31, 2010. The lower number of days worth of sales is mainly due to the increased conversion of long lead time raw materials to accommodate the nine month period increased sales.

We generated cash from operations of approximately $2.1 million, which included a one time gain on a legal settlement of $750,000, for the nine months ended September 30, 2011, compared to cash used in operations of approximately $1.0 million for the same period of 2010, an increase of approximately $3.1 million.

In the nine month period ended September 30, 2011 we used approximately $459,000 for the purchase of property and equipment as compared to purchases amounting to approximately $350,000 for the same period in 2010.

We used cash from financing activities of approximately $105,000 during the first nine months of 2011, a decrease of approximately $1.9 million compared with the same period in 2010. The decrease in cash from financing resulted primarily from a 2010 private placement sale of our common shares of approximately $2.8 million net of placement costs reduced in the same period by $1 million which was used to pay off our line of credit balance.

We currently have approximately $3.6 million in debt outstanding, which was borrowed under industrial revenue bonds we originally used for the purchase and renovation of our Clearwater, Florida facility, and is collateralized by a mortgage. Subsequently on October 31, 2011 we established new credit facilities with PNC Bank which included a 100% purchase of the industrial revenue bonds by PNC Bank.

The bonds, which are being amortized over a 20-year term, have a balloon payment due upon maturity in December 2018 and bear interest at an effective fixed rate of 5.425% via an embedded derivative interest rate swap. Scheduled maturities of this indebtedness are approximately $70,000 remaining for 2011, and $145,000, $155,000, $160,000 and $165,000 for 2012, 2013, 2014 and 2015, respectively.

We had approximately $5.4 million in cash and cash equivalents at September 30, 2011. We believe our cash on hand, as well as anticipated cash flows from operations, will be sufficient to meet our operating cash commitments for the next year. Should additional funds be required, we have secured additional borrowing capacity with PNC Bank. (see below)

As of October 31, 2011 we have secured a $6 million revolving line of credit facility with PNC Bank. Previous to this we had an $8 million secured revolving line of credit facility with RBC Bank (USA) which at September 30, 2011 had a zero balance. Advances under our new $6 million line of credit are due on demand and bear interest at a rate of LIBOR plus 1.75% and are secured by a perfected first security interest in our inventory, accounts receivable, and certain other business assets.

In addition we have a separate additional credit facility with PNC Bank for up to $1 million specific to financing new equipment purchases. This credit facility provides for a one year draw up period followed by a 5-year term period and bears interest at LIBOR plus 2.25% and is secured by a perfected first security interest in the new equipment purchased. We also have the option of financing purchased equipment at 90% of the cost through either a traditional loan at the time of purchase.

Subsequent available borrowings for both these line of credit facilities with PNC Bank are subject to a borrowing base utilizing a percentage of eligible receivables, inventories, and any assigned cash along with certain financial ratios, specifically maintaining: a ratio of debt to tangible net worth of less than 2.0 to 1.0, a ratio of total funded debt to EBITDA of less than 3.25 to 1.0 excluding the industrial revenue bond note balance which had an original principal amount of $4.0 million, and a ratio of minimum debt service coverage of 1.5 to 1.0 measured on a rolling four quarter basis.

At September 30, 2011 we were in full compliance with the loan covenants and ratios of both the RBC credit facilities. According to our most recent borrowing base calculation, we had approximately $4.0 million total availability under both the previous $8 million RBC credit line and initially for our current PNC Bank credit line, of which we currently have a zero balance. We also have availability of the full $1 million under the equipment line of credit.

Our future contractual obligations for agreements with initial terms greater than one year and agreements to purchase materials in the normal course of business are summarized as follows (in thousands):

| Description | Years Ending December 31, 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating leases | $62 | $251 | $227 | $12 | - | - |
| Employment agreements | 250 | 1,074 | 1,091 | 104 | - | - |
| Purchase Commitments | 4,357 | - | - | - | - | - |

### Critical Accounting Estimates

In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our report on Form 10-K for the year ended December 31, 2010 which we filed in March 2011.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, fair valued liabilities, sales returns and discounts, and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

### Inventory reserves

When necessary, we maintain reserves for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience, and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.

### Long-lived assets

We review long-lived assets which are held and used, including property and equipment and intangible assets, for impairment whenever changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Such evaluations compare the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset over its expected useful life and are significantly impacted by estimates of future prices and volumes for our products, capital needs, economic trends and other factors that are inherently difficult to forecast. If the asset is considered to be impaired, we record an impairment charge equal to the amount by which the carrying value of the asset exceeds its fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique.

### Liabilities valued at fair value

We have used derivative financial instruments to hedge exposures to cash-flow risks or market-risks (see Note 7). In addition, certain financial instruments, such as warrants, which are indexed to our common stock, are classified as liabilities when either (a) the holder possesses rights to net-cash settlement or (b) physical or net-share settlement is not within our control. In such instances, net-cash settlement is assumed for financial accounting and reporting purposes, even when the terms of the underlying contracts do not provide for net-cash settlement. Such financial instruments are initially recorded, and continuously carried, at fair value. (see Note 5)

Determining the fair value of these instruments involves judgment and the use of certain relevant assumptions including, but not limited to, interest rate risk, historical volatility and stock price, estimated life of the derivative, anti-dilution provisions, and conversion/redemption privileges. The use of different assumptions or changes in those assumptions could have a material effect on the estimated fair value amounts.

### Share-based Compensation

Under our stock option plan, options to purchase common shares of common stock of the Company may be granted to our key employees, officers, directors and consultants by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718 *Compensation-Stock Compensation* with option expense amortized over the vesting period based on the binomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense.

### Income Taxes

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.

We have net operating loss and tax credit carry forwards available in certain jurisdictions to reduce future taxable income. Future tax benefits for net operating loss and tax credit carry forwards are recognized to the extent that realization of these benefits is considered more likely than not. This determination is based on the expectation that related operations will be sufficiently profitable or various taxes, business and other planning strategies will enable us to utilize the operating loss and tax credit carry forwards. We cannot be assured that we will be able to realize these future tax benefits or that future valuation allowances will not be required. To the extent that available evidence raises doubt about the realization of a deferred income tax asset, a valuation allowance is established.

It is our policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent that the probable tax outcome of these uncertain tax positions changes, such changes in estimate will impact the income tax provision in the period in which such determination is made. At September 30, 2011, we believe we have appropriately accounted for any unrecognized tax benefits. To the extent we prevail in matters for which a liability for an unrecognized tax benefit is established or we are required to pay amounts in excess of the liability, our effective tax rate in a given financial statement period may be affected.

Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which maybe as much as 20 years while we have unused net operating loss carryforwards), we are subject to income tax audits in the jurisdictions in which we operate.

### Inflation

Inflation has not materially impacted the operations of our company.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements at this time.

### Recent Accounting Pronouncements

See Note 4.

## Market risk

As filed, 1,016 characters.

Our short-term investments consist of cash, cash equivalents and overnight investments. Additionally, we have an embedded long term interest rate swap related to our subsequent refinancing of our industrial revenue bonds through PNC Bank, which mitigates our exposure to market rate fluctuations and effectively converts our variable rate interest payments on these bonds to a fixed rate. As such we do not believe we are exposed to significant interest rate risk while this interest rate swap remains in place. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid overnight money market investments or short term certificates of deposit. If a 10% change in interest rates were to have occurred on September 30, 2011, this change would not have had a material effect on the fair value of our investment portfolio nor our bond interest expense as of that date.

## Controls and procedures

As filed, 1,773 characters.

### Evaluation of Disclosure Controls and Procedures

We have carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2011. Based upon that evaluation, our CEO and CFO concluded that, as of the end of that period, our disclosure controls and procedures are effective in providing reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (b) such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

### Changes in Internal Controls

There were no changes in our internal control over financial reporting (as defined in Rules 13(a)-15(f) and 15(d)-15(f)) during the nine months ended September 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,517 characters.

### Our Domestic and International Growth Is Subject to a Number of Economic Risks

Although there have been some recent positive economic indicators over the past nine months when compared to the significant downturn of 2008 and 2009, uncertainty still exists as to the overall rate and stability of the recovery. Global gross domestic product growth continues to be led by emerging markets, particularly in Brazil, Russia, India and China, while in established economies in Europe, the recovery remains sluggish due to the unwinding of fiscal stimuli, lingering high unemployment, concerns over European sovereign debt issues and the tightening of government budgets. As a result our revenues could be affected by further disruptions in Europe or in other economies including domestically.

In the U.S. since the economic downturn, unemployment still remains high and the housing market remains depressed. There can be no assurance that any of the recent economic improvements will be broad-based and sustainable, or that they will enhance conditions in markets relevant to us. Further, there can be no assurance that we will not experience further adverse effects that may be material to our cash flows, competitive position, financial condition, results of operations, or our ability to access capital. These economic developments have not impaired our ability to access credit markets and finance our operations to date, however there can be no assurance that conditions in the future will have not have an impact.

Filed Nov 14, 2011.
Source: SEC EDGAR, the filing index for accession 0001140361-11-053005. Last ingested by Listed: Nov 5, 2026, 13:09 ET. No prices; not investment advice.
